The Trustees of Columbia University in the City of New York (20240294643). COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS simplified abstract

COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS

Organization Name

The Trustees of Columbia University in the City of New York

Inventor(s)

Benjamin Izar of New York NY (US)

Johannes C. Melms of New York NY (US)

Pratiksha Thakore of Cambridge MA (US)

Katie Geiger-schuller of Cambridge MA (US)

Aviv Regev of Cambridge MA (US)

Chris Frangieh of Cambridge MA (US)

COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240294643 titled 'COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS

• • Simplified Explanation:**

The patent application focuses on methods to target CD58 signaling to enhance antitumor immunity and overcome resistance to checkpoint blockade therapy. Gene signatures associated with immune fitness are identified, leading to the discovery of markers and therapeutic targets for immunotherapy resistance.

• • Key Features and Innovation:**

- Identification of gene signatures associated with immune fitness - Targeting CD58 signaling to enhance antitumor immunity - Overcoming resistance to checkpoint blockade therapy - Discovery of markers and therapeutic targets for immunotherapy resistance

• • Potential Applications:**

- Cancer immunotherapy - Precision medicine - Drug development targeting CD58 signaling

• • Problems Solved:**

- Resistance to checkpoint blockade therapy - Lack of effective markers for immunotherapy resistance - Inability to enhance antitumor immunity effectively

• • Benefits:**

- Improved outcomes in cancer treatment - Enhanced effectiveness of immunotherapy - Personalized treatment options based on gene signatures

• • Commercial Applications:**

Title: Enhancing Cancer Immunotherapy through CD58 Signaling Targeting Potential commercial uses include developing targeted therapies for cancer treatment, licensing gene signature analysis tools for precision medicine applications, and partnering with pharmaceutical companies for drug development targeting CD58 signaling.

• • Questions about CD58 Signaling:**

1. How does targeting CD58 signaling enhance antitumor immunity? 2. What are the potential implications of overcoming resistance to checkpoint blockade therapy through CD58 signaling targeting?

Original Abstract Submitted

methods of targeting cd58 signaling to enhance antitumor immunity and overcome resistance to checkpoint blockade therapy. gene signatures associated with immune fitness were identified. markers and therapeutic targets for such immunotherapy resistance.